Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

CVRX
CVRx, Inc. Common Stock
stock NASDAQ

At Close
May 30, 2025 3:59:30 PM EDT
6.63USD-2.500%(-0.17)241,528
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 29, 2025 8:20:30 AM EDT
6.99USD+2.794%(+0.19)0
After-hours
May 29, 2025 4:00:30 PM EDT
6.80USD+0.147%(+0.01)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:59AM EST  CVRx Sees Q4 2021 Revenue $3.6M-$3.7M Vs $4.09M Est; Sees FY21 Revenue $13M-$13.1M Vs $13.63M Est   Benzinga
08:00AM EST  CVRx, Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2021 revenue results, and provided a 2022 business outlook.   GlobeNewswire Inc
Dec 21, 2021
04:13PM EST  Oak Street Health, Aligos Therapeutics, CVRx, Tivity, Oyster Point Pharma To Present At JP Morgan Healthcare Conference Jan. 10-12, 2022   Benzinga
04:05PM EST  CVRx to Present at the 40th Annual J.P. Morgan Healthcare Conference   GlobeNewswire Inc
Nov 16, 2021
04:05PM EST  CVRx, Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced thatthe management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.   GlobeNewswire Inc
Nov 5, 2021
09:28AM EDT  CVRx Sees FY21 Sales $13.3M-$13.9M vs. $13.76M Est.   Benzinga
09:28AM EDT  CVRx Q3 EPS $(0.30) Beats $(0.37) Estimate, Sales $3.40M Beat $3.28M Estimate   Benzinga
Nov 4, 2021
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Oct 21, 2021
04:05PM EDT  CVRx to Report Third Quarter 2021 Financial and Operating Results   GlobeNewswire Inc
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 17, 2021
08:02AM EDT  CVRx Reports Will Be Added To Russell 2000, 3000 Indices As Of Sept. 20   Benzinga
08:00AM EDT  CVRx Added to Russell 2000 and 3000 Indexes   GlobeNewswire Inc
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Aug 4, 2021
05:17PM EDT  CVRx Sees Q3 Sales $3.3M-$3.6M, Sees FY21 Sales $13.3M-$13.9M   Benzinga
05:16PM EDT  CVRx Q2 Sales $3.1M, Up 150% YoY   Benzinga
04:05PM EDT  CVRx, Inc. (NASDAQ: CVRX) (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2021.   GlobeNewswire Inc
Jul 26, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021   Benzinga
08:23AM EDT  William Blair Initiates Coverage On CVRx with Outperform Rating   Benzinga
08:09AM EDT  Canaccord Genuity Initiates Coverage On CVRx with Buy Rating, Announces Price Target of $30   Benzinga
06:05AM EDT  JP Morgan Initiates Coverage On CVRx with Overweight Rating, Announces Price Target of $24   Benzinga
05:48AM EDT  Piper Sandler Initiates Coverage On CVRx with Overweight Rating, Announces Price Target of $26   Benzinga
Jul 21, 2021
05:28PM EDT  CVRx to Report Second Quarter 2021 Financial and Operating Results   GlobeNewswire Inc
Jul 13, 2021
06:17PM EDT  Last IPO Week Was The Busiest In Over A Decade   Benzinga
05:59PM EDT  A Shortened IPO Holiday Week   Benzinga
Jul 12, 2021
08:00AM EDT  CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan   GlobeNewswire Inc
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jul 6, 2021
07:05AM EDT  Treo Ventures Announces the Successful IPO of its Portfolio Company CVRx(r)   PR Newswire
Jul 2, 2021
04:05PM EDT  CVRx, Inc. Announces Closing of Initial Public Offering and Full   GlobeNewswire Inc
07:38AM EDT  The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures   Benzinga
Jun 30, 2021
01:10PM EDT  CVRx Shares Open For Trade At $26.25; IPO Priced At $18/Share   Benzinga
12:16PM EDT  CVRx Indicating $25 On 447K Shares   Benzinga
10:55AM EDT  CVRx Indicating $23.40 On 225K Shares   Benzinga
10:43AM EDT  CVRx Shares Indicating $23.40   Benzinga
09:32AM EDT  CVRx Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $18/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC